CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier
CAR-T cell therapy is an effective treatment for CNSL patients harboring TP53 mutations and has the same efficacy as traditional treatment methods. Additionally, CAR-T cells may be more effective for TP53+ CSNL patients with a non-GCB classification.
Authors
- Yuelu Guo
- Miaomiao Cao (ORCID: https://orcid.org/0000-0002-4863-4454)
- Danyang Li (ORCID: https://orcid.org/0000-0002-4795-5766)
- Zhonghua Fu
- Kai Hu
- Qinlong Zheng
- Fan Yang
- Rui Liu
- Lixia Ma
- Biping Deng
- Alex H. Chang
- Xiaoyan Ke
Institutions
- Beijing Tongren Hospital (CN)
- Peking University (CN)
- Fudan University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-13
- DOI
- https://doi.org/10.3389/fmed.2025.1731589
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00